論文・技術情報追加のお知らせ

1. Tacrolimus related diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome: an observational, retrospective, pharmacovigilance study.

タクロリムス使用でDKAとHHNSのリスク増加が確認された

対象DB：FAERS

2. Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database.

オルリスタットの新しい副作用を発見し、安全性評価が必要

対象DB：FAERS

3. Association between PCSK9 inhibitors and acute kidney injury: a pharmacovigilance study.

PCSK9阻害剤は急性腎障害(AKI)と関連しない可能性があり、併用薬での影響も調査された

対象DB：FAERS

4. The global burden and trend of Clostridioides difficile and its association with world antibiotic consumption, 1990-2019.

CDIは全球的に増加しており、抗生物質使用と強く関連している

対象DB：FAERS

5. Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System.

プラミペキソールとアリピプラゾールは衝動性を引き起こし、社会的影響が大きい

対象DB：FAERS

6. A real-world drug safety surveillance study of lenvatinib from the FAERS database.

レムバチニブには新たな副作用があり、慎重な監視が必要

対象DB：FAERS

7. Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration's adverse event reporting system databases.

ゲパン薬は副作用に違いがあり、個別対応が必要

対象DB：FAERS

8. Safety assessment of neurokinin-1 receptor antagonist: real-world adverse event analysis from the FAERS database.

アプレピタント、フォサプレピタント、ネチュピタントは異なる副作用プロファイルを持つ

対象DB：FAERS

9. A Biologic With Otologic Consequences: Analysis of Hearing Loss and Teprotumumab Using the FDA Adverse Event Reporting System.

テプロツムマブは聴力障害のリスクが高く、年齢が影響する

対象DB：FAERS

10. Adverse events associated with teriparatide:a real-world disproportionality analysis of the Fda adverse event reporting system (faers).

テリパラチドは筋骨格系障害のリスクが高い

対象DB：FAERS

11. The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database.

ティルゼパチドはGLP-1RAと同様の安全性リスクを示す

対象DB：FAERS

12. A pharmacovigilance study assessing risk of angioedema with angiotensin receptor blockers using the US FDA adverse event reporting system.

ロサルタンとイルベサルタンは高い血管浮腫リスクが示唆される

対象DB：FAERS

13. Real-world safety profile of eculizumab: an analysis of FDA adverse event reporting system and systematic review of case reports.

エクリズマブ使用時、感染症リスクに注意が必要

対象DB：FAERS

14. Systematic analysis of the adverse effects of commonly used clinical tetracycline drugs based on the FAERS database.

テトラサイクリン系薬剤は多様な副作用を示し、注意が必要

対象DB：FAERS

15. Cardiovascular toxicities of selective ret-specific tyrosine kinase inhibitors: a pharmacovigilance study based on the united states food and drug administration adverse event reporting system database.

選択的RET-TKIは心血管毒性を引き起こし、迅速な対応が必要

対象DB：FAERS

16. Amiodarone-Induced Anaphylaxis.

アミオダロン誘発アナフィラキシーは稀で、原因不明。迅速な治療が重要

対象DB：FAERS

17. Ocular adverse events associated with Platins: a disproportionality analysis of pharmacovigilance data and extensive systematic review of case reports.

プラチナ製剤の抗がん剤は眼部副作用のリスクが高い

対象DB：FAERS

18. Ocular Adverse Effects of Over-the-Counter Cosmetics and Personal Care Products Reported to the Food and Drug Administration.

化粧品による眼部副作用は増加傾向にあり、炎症や不快感が多い

対象DB：FAERS

19. Safety profiles of doxycycline, minocycline, and tigecycline in pediatric patients: a real-world pharmacovigilance analysis based on the FAERS database.

小児におけるテトラサイクリンの副作用は、ミノサイクリンが重篤で多い

対象DB：FAERS

20. Differences in hypersensitivity reactions and gadolinium deposition disease/symptoms associated with gadolinium exposure to gadolinium-based contrast agents: new insights based on global databases VigiBase, FAERS, and IQVIA-MIDAS.

ガドリニウム造影剤のアレルギー反応や皮膚硬化症のリスクに差異が見られる

対象DB：FAERS,VigiBase

21. Post-marketing safety concerns with relugolix: a disproportionality analysis of the FDA adverse event reporting system.

リルゴリクスの新たな副作用として、勃起不全や性欲減退が報告された

対象DB：FAERS

22. Cardiovascular adverse events associated with PARP inhibitors for ovarian cancer: a real world study (RWS) with Bayesian disproportional analysis based on the FDA adverse event reporting system (FAERS).

EOC治療において、ニラパリブは心血管イベントリスクが高いため、注意が必要

対象DB：FAERS

23. Gabapentinoids-Related Delirium Adverse Events: A Real-World Study from 2004 to 2022 Based on FAERS.

ガバペンチン類は、特に高齢者と男性でせん妄リスクが高い

対象DB：FAERS

24. Muscular toxicity of colchicine combined with statins: a real-world study based on the FDA adverse event reporting system database from 2004-2023.

コルヒチンとスタチンの併用で筋肉障害のシグナル強度が高い

対象DB：FAERS

25. Adverse events associated with inclisiran: a real-world disproportionality analysis based on the FAERS database.

RWでのインクリシランの副作用を評価

対象DB：FAERS

26. Detection and analysis of the safety profile of talazoparib based on FAERS database.

タラゾパリブの副作用に関する安全性を評価

対象DB：FAERS

27. Phosphodiesterase-5 inhibitors and hearing impairment: a disproportionality analysis using the US food and drug administration adverse event reporting system.

PDE-5阻害剤使用と聴覚障害の関連性を調査

対象DB：FAERS

28. Voriconazole-induced central nervous system toxicity: a pharmacovigilance study based on FDA adverse event reporting system (FAERS) database.

ボリコナゾールによる中枢神経毒性の調査

対象DB：FAERS

29. Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA's adverse event reporting system: a case control pharmacovigilance study.

CDK4/6阻害薬の副作用に差があり、選択に影響

対象DB：FAERS

30. Drugs associated with reversible cerebral vasoconstriction syndrome: A pharmacovigilance study in vigiBase((R)).

RCVSは抗うつ薬やトリプタンに関連し、新たなシグナルも確認

対象DB：VigiBase

31. Fasudil hydrochloride and ozagrel sodium combination therapy for patients with aneurysmal subarachnoid hemorrhage: a cross-sectional study using a nationwide inpatient database.

ファスジル単独治療と併用治療で死亡率に差はない

対象DB：DPC

32. Intraoperative recurrent laryngeal nerve monitoring for esophagectomy: A national cohort study.

IONMは食道がん手術でRLN麻痺と呼吸合併症を減少させる

対象DB：DPC

33. Impact of Collagenase Injection on Dupuytren Disease Treatment in Japan: A Comprehensive Survey of Trends.

CCHの撤退で手術が増加し、治療機会が減少

対象DB：NDB

34. Survey of pharyngeal foreign bodies in Japan: An ecological study using the nationwide claims data.

魚骨などによる異物誤飲は地域差と季節性がある

対象DB：NDB

35. Assessment of cancer risk associated with 7-nitroso-3-(trifluoromethyl)-5,6,7,8-tetrahydro[1,2,4] triazolo-[4,3-a]pyrazine-contaminated sitagliptin use: A retrospective cohort study.

シタグリプチン汚染による癌リスク増加は認められず

対象DB：NDB

36. Shifting paradigms in endoscopic sinus surgery: a comprehensive analysis from Japan's national database.

日本でESS分類導入後、外来手術が増加

対象DB：NDB

37. Factors associated with long-term opioid use among patients with axial spondyloarthritis or psoriatic arthritis who initiated opioids.

長期オピオイド使用は喫煙や併存症と関連

対象DB：CPRD

38. Large language model aided automatic high-throughput drug screening using self-controlled cohort study.

自動薬物スクリーニングで新治療法と副作用を発見

対象DB：CPRD

39. Systemic sclerosis and cancer in the UK: An epidemiological analysis using the Clinical Practice Research Datalink.

全身性硬化症後に癌のリスクが増加

対象DB：CPRD

40. Prevalence, risk factors and characterisation of individuals with long COVID using Electronic Health Records in over 1.5 million COVID cases in England.

長期COVIDの症状は女性や肥満者で多く見られる

対象DB：CPRD

41. Impact of co-resident health and living alone on risk of hospital admission for people with Parkinson's disease.

パーキンソン病患者の緊急入院リスクは独居で増加

対象DB：CPRD